User:Teilhardo/new article name here

Synthetic Genomics

Synthetic Genomics Inc. (SGI), is a private company that uses a pioneering foundation in the field of Synthetic genomics and cell biology to improve the sustainability of existing biological products and create new approaches to the development of vaccines, biofuels, pharmaceuticals and humanized organs. This foundation is built with core expertise in bioinformatics, metagenomics, automated liquid handling workflows and proprietary reagents that together form a bottom up approach to optimize the effectiveness of sustainable innovation in the growing application of synthetic biology to existing biologic products. Many of these products are developed in collaboration with other industry leaders including ExxonMobil, United Therapeutics, Novartis and ADM.

Synthetic Genomics was founded in part by J. Craig Venter. Venter's previous company, Celera Genomics, was a driving force in the race to sequence the Human Genome. The firm takes its name from the phrase synthetic genomics which is a scientific discipline of synthetic biology related to the generation of organisms artificially using genetic material.

2006
SGI was founded in the spring of 2005 by J. Craig Venter, Ph.D, Nobel Laureate Hamilton O. Smith, M.D., Juan Enriquez and David Kiernan, M.D., J.D.

2007
SGI formed a collaboration with BP to develop and commercialize microbial-enhanced solutions to increase the conversion and recovery of subsurface hydrocarbons.

2009
In 2009, SGI received funding from ExxonMobil to produce biofuels on an industrial-scale using recombinant algae and other microorganisms.

2010
Life Technologies became an investor in Synthetic Genomics, Inc. . In the same year, Synthetic Genomics also spun off a new subsidiary, Synthetic Genomics Vaccines Inc., to develop next generation vaccines

2012
The company purchased an 81 acre site in Southern California's Imperial valley to produce algae fuel for their collaboration with Exxon Mobil. . They also signed a collaborative agreement with New England Biolabs to Launch Gibson Assembly™ Master Mix Product for Synthetic and Molecular Biology Applications

2014
In 2014 SGI expanded into the field of organ transplantation with a collaborative agreement with United Therapeutics valued at $50M and brought in Oliver Fetzer, Ph.D., MBA as CEO

2015
In 2015 SGI launched its first instrument, the BioXp™ 3200 System.

Products
Commercialized products sold by Synthetic Genomics are sold through its subsidiary company SGI-DNA. Many of these products utilize the Gibson assembly method which was created by Dan Gibson (currently the Vice President of DNA Technology at SGI) in collaboration with the J. Craig Venter Institute in 2009.

Reagents

 * The Gibson Assembly® HiFi 1 Step Kit
 * The Gibson Assembly® Ultra Kit
 * Gibson Assembly® Site-Directed Mutagenesis Kit
 * Gibson Assembly® Vectors

Instruments

 * BioXp™ 3200 System

Software

 * Archetype® software